University of Groningen, University Medical Center Groningen, Department of Otorhinolaryngology, Head and Neck Surgery, Hanzeplein 1, 9713, GZ, Groningen, the Netherlands.
University of Groningen, University Medical Center Groningen, Department of Otorhinolaryngology, Head and Neck Surgery, Hanzeplein 1, 9713, GZ, Groningen, the Netherlands.
Eur J Surg Oncol. 2021 Aug;47(8):1816-1827. doi: 10.1016/j.ejso.2021.02.029. Epub 2021 Mar 6.
Head and neck cancers (HNC) are relatively fast-growing tumours, and delay in treatment initiation is associated with tumour progression and adverse outcome. An overview of factors contributing to delay can provide critical insights on necessary adjustments to optimize care pathways. This systematic review aims to identify factors associated with delay and summarize the effect of delay on oncological outcome measures.
A search strategy was conducted according to PRISMA guidelines to search electronic databases for studies assessing the carepathway interval (days between first visit in head and neck oncology center and treatment initiation) and/or time-to-treatment-initiation interval (days between histological diagnosis and treatment initiation) and 1) determinants of delay and/or 2) effect of delay on outcome within these timeframes. Due to heterogeneity between included studies, a meta-analysis was not possible.
Fifty-two studies were eligible for quantitative analysis. Non-Caucasian race, academic setting, Medicaid/no insurance and radiotherapy as primary treatment were associated with delay. Advanced tumour stage was related to increased time-to-treatment initiation in the four common sites combined (oral cavity, oropharynx, hypopharynx, larynx). Separate determinants for delay in different tumour locations were identified. In laryngeal, oral cavity cancer and the four common HNC sites combined, delay in start of treatment is associated with decreased overall survival, although no cut-off time point could be determined.
Race, facility type, type of insurance and radiotherapy as primary treatment were associated with delay and subsequent inferior survival in the four common sites combined.
头颈部癌症(HNC)是生长较快的肿瘤,治疗启动的延迟与肿瘤进展和不良预后相关。对头颈部癌症患者延迟治疗的原因进行全面评估,有助于深入了解需要进行哪些调整以优化诊疗路径。本系统综述旨在确定与延迟相关的因素,并总结延迟对肿瘤学结局指标的影响。
根据 PRISMA 指南制定检索策略,在电子数据库中检索评估头颈部肿瘤中心首诊与治疗启动间隔(即首次就诊至治疗启动的天数)和/或首次就诊至治疗启动间隔(即组织学诊断至治疗启动的天数)以及 1)延迟的决定因素和/或 2)这些时间框架内延迟对结局影响的研究。由于纳入研究之间存在异质性,因此无法进行荟萃分析。
52 项研究符合定量分析的纳入标准。非白种人种族、学术环境、医疗补助/无保险和放疗作为主要治疗方式与延迟相关。在口腔、口咽、下咽和喉这四个常见部位中,肿瘤分期较晚与治疗启动时间延长相关。在不同肿瘤部位也确定了单独的延迟决定因素。在喉癌、口腔癌和这四个常见的头颈部癌症部位中,治疗开始的延迟与总生存时间降低相关,尽管未能确定具体的时间截点。
种族、医疗机构类型、保险类型和放疗作为主要治疗方式与延迟以及这四个常见部位的总生存时间降低相关。